Compare SELF & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SELF | RFL |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Real Estate |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 61.1M |
| IPO Year | 1997 | 2017 |
| Metric | SELF | RFL |
|---|---|---|
| Price | $5.21 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.1K | ★ 89.3K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 5.64% | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $12,530,280.00 | $917,000.00 |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $34.27 | ★ N/A |
| Revenue Growth | 2.79 | ★ 43.96 |
| 52 Week Low | $4.73 | $1.12 |
| 52 Week High | $5.83 | $3.19 |
| Indicator | SELF | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 63.57 | 72.54 |
| Support Level | $5.19 | $1.41 |
| Resistance Level | $5.22 | $1.64 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 81.67 | 75.00 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.